DERM - NASDAQ
Journey Medical Corporation
$6.22
+2.0%Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
At a Glance
Live SnapshotJourney Medical Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Journey Medical Corporation Income Statement
DERM • NASDAQ
| Journey Medical Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
61.9M | 56.1M | 79.2M | 73.7M | 63.1M | 44.5M | 34.9M | 42.3M | 4.5M | 22.6M | 7.3M | 7.3M | |
GROSS PROFIT | ||||||||||||
(25.2M) | (20.9M) | (26.7M) | (30.8M) | (32.1M) | (14.6M) | (10.5M) | (1.2M) | (0.0) | (0.0) | (0.0) | (0.0) | |
36.7M | 35.3M | 52.5M | 42.9M | 31.1M | 29.9M | 24.4M | 41.2M | 4.5M | 22.6M | 7.3M | 7.3M | |
OPERATING INCOME | ||||||||||||
(44.8M) | (48.9M) | (54.6M) | (70.4M) | (65.9M) | (22.1M) | (19.1M) | (255.1M) | (304.9M) | (113.2M) | (87.1M) | (39M) | |
(44.4M) | (40.2M) | (43.9M) | (59.5M) | (39.8M) | (0.0) | (19.1M) | (172.6M) | (71.9M) | (30M) | (17.7M) | (8.3M) | |
(480K) | (9.9M) | (7.5M) | (10.9M) | (16.6M) | (0.0) | (0.0) | (80.5M) | (104.4M) | (83.2M) | (66.8M) | (30.7M) | |
-8.2M | -13.7M | -2.1M | -27.5M | -34.9M | 7.9M | 5.3M | -214M | -300.3M | -90.6M | -79.8M | -31.7M | |
PRE-TAX INCOME | ||||||||||||
(3.7M) | (2.7M) | (1.7M) | (2M) | (7M) | (698K) | (255K) | (15.6M) | (8.1M) | (1.5M) | (147K) | (153K) | |
-3.1M | -1.9M | -1.4M | -2M | -7M | -698K | -255K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
(0.0) | -1.1M | (3.1M) | (0.0) | (9.5M) | (22.1M) | (0.0) | (2M) | (128.6M) | (0.0) | (2.5M) | (0.0) | |
-3.2M | -934K | -1.6M | -2M | -7.5M | -698K | -255K | -7.8M | -2.9M | 1.5M | 749K | -146K | |
-11.4M | -14.6M | -3.6M | -29.6M | -42.4M | 7.2M | 5M | -221.7M | -303.3M | -89.1M | -79M | -31.8M | |
NET INCOME | ||||||||||||
(60K) | (61K) | (221K) | (63K) | (1.6M) | (1.9M) | (1.4M) | -194K | (0.0) | (0.0) | -622K | (31K) | |
-11.4M | -14.7M | -3.9M | -29.6M | -44M | 5.3M | 3.6M | -221.5M | -303.3M | -89.1M | -78.4M | -31.9M |
SEC Filings
DERM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 25, 2026 | 2026 | |
S-3 S-3 N/A | January 15, 2026 | January 15, 2026 | ||
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 26, 2025 | September 25, 2025 | 2025 |
Related Guides
Continue your DERM research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.